The failure and termination of the MK-1308A clinical development program represents a significant sunk R&D cost and a gap in the oncology pipeline. This setback increases pressure on the company to optimize its remaining pipeline and improve clinical trial efficiency to ensure future revenue growth.
Filing excerpt
A pre-specified interim analysis of the Phase 3 LITESPARK-012 study found that... the combination regimen of MK-1308A (an investigational fixed dose coformulation of Keytruda and the anti-CTLA-4 antibody quanvonlimab) plus Lenvima, did not show a statistically significant improvement in the dual primary endpoints...
What this signalsFilings often name leadership changes, deals and spending plans.
sec-10qmarginPressureGet every 10-Q signal for Merck and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Merck this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/5969e5b0-cc7d-4453-8c3e-bdad86f478a9 returns this record as JSON. POST /v1/companies/enrich returns every signal for merck.com.
{
"signal_id": "5969e5b0-cc7d-4453-8c3e-bdad86f478a9",
"signal_type": "sec-10q",
"signal_subtype": "marginPressure",
"detected_at": "2026-05-05T08:48:22.077+00:00",
"company": {
"name": "Merck",
"domain": "merck.com"
},
"data": {
"detail": "The failure and termination of the MK-1308A clinical development program represents a significant sunk R&D cost and a gap in the oncology pipeline. This setback increases pressure on the company to optimize its remaining pipeline and improve clinical trial efficiency to ensure future revenue growth.",
"metrics": {
"timeframe": "current_quarter"
},
"summary": "Merck discontinues MK-1308A oncology program after Phase 3 trial fails to meet endpoints",
"excerpts": "A pre-specified interim analysis of the Phase 3 LITESPARK-012 study found that... the combination regimen of MK-1308A (an investigational fixed dose coformulation of Keytruda and the anti-CTLA-4 antibody quanvonlimab) plus Lenvima, did not show a statistically significant improvement in the dual primary endpoints...",
"relevance": 0.8,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/310158/000162828026029802/mrk-20260331.htm",
"filing_date": "2026-05-04",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "03/31",
"sales_relevance": "Efficiency tools needed",
"signal_category": "financial"
}
}
curl https://signals.autobound.ai/v1/signals/5969e5b0-cc7d-4453-8c3e-bdad86f478a9 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"merck.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.